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2 Atherosclerosis and Alzheimer's Disease 
Abstract 
Several animal studies have brought the cholinergic hypothesis of 
Alzheimer's Disease (AD) into question. In addition, recent clinical 
studies have shown that the number of neuritic plaques and neurofibrillary 
tangles does not yield a conclusive diagnosis of AD. A reassessment of 
risk factors involved in AD development has led to findings that 
atherosclerosis is associated with dementia. The present study is a 
clinical analysis, through the use of case studies, of the relationship 
between atherosclerosis severity, based on autopsy results, and AD 
severity, based on scores from cognitive tests and fu nctional 
assessments, as well as autopsy results. The age of AD onset as it 
relates to atherosclerosis has also been examined. The age of 
participants at AD onset occurring with atherosclerosis has been 
determined both through examination of medical records and interviews 
with family members. This is an ongoing study. Unfortunately, no results 
supporting a relationship between atherosclerosis and AD have yet been 
found; however, future results may indicate a relationship. 
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A Case Study Analysis of the Relationship Between Atherosclerosis and 
Alzheimer's Disease 
Four million Americans are currently afflicted by Alzheimer's 
disease (AD), and due to an aging population, this number is expected to 
increase by 400% in 50 years. In the U.S., 10% of individuals aged 65 will 
develop AD, and 47% of those aged 85 or more will also develop the 
disease (de la Torre, 1997; Morrison-Bogorad, Creighton, & Phelps, 1997). 
In the general population, there is a 15% lifetime risk of developing AD 
(Post et aI., 1997). Alzheimer's disease affects not only the lives of those 
diagnosed but also the lives of both the family and friends who provide 
care and support. 
The onset of AD is typically marked by a decrease in ability to 
recall things such as minor appointments although these initial memory 
lapses are generally not noticed by family, friends, and co-workers. As 
the disease progresses, daily life and self care become impaired, and 
personality changes begin to occur. In the final stages of the disease, 
speech becomes limited to a single word and then nonexistent. Movement 
ability slowly decays until the patient can no longer hold up their head 
(Reisberg, 1988). 
The basal forebrain is one of the major areas compromised in AD 
(Candy et aI., 1983; Whitehouse, P., Price, D., Struble, R., Clarke, A., Coyle, 
J., Delong, M., 1982). This brain region consists of the medial septal area 
(MSA), which sends projections to the hippocampus, and the nucleus 
basalis magnocellularis basalis (NMB), which sends projections to the 
cortex. As stated above, one of the first recognized impairments in AD is 
memory loss. Decline in memory is presumably associated with damage to 
the hippocampus. Often the first neuronal structure compromised in AD, 
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the hippocampus is involved in learning and memory (DeJong, R., 1969; 
Garcia, J., 1970; Thomas, G., 1971; Westerhof, P., 1972). Braak et al. have 
documented increasing damage to the hippocampus throughout the 
progressive stages of AD. 
The nucleus basalis magnocellularis sends projections to both the 
amygdala and the cerebral cortex. As part of the limbic system, the 
amygdala plays an important role in emotional behavior. Therefore, 
destruction of this neuronal formation could account for changes of 
personality noted in AD patients during the later stages of the disease. 
The cerebral cortex, particularly the premotor and supplemental motor 
cortices of the frontal cortex, is involved in the planning and execution of 
movement (Carlson, 1994). Decline in these functions occurs throughout 
the progression of AD, as well. 
The basal forebrain accounts for 80-95% of the acetylcholine (ACh) 
neurotransmitter in the brain (Dornan et aI., 1996). As a result, with the 
destruction of the basal forebrain comes a depletion of the acetylcholine 
neurotransmitter. This finding has led to the development of the 
"cholinergic hypothesis." The hypothesis states that acetylcholine 
decrease, brought on by AD, leads to the cognitive deficits associated 
witl, Alzheimer's disease (W. A. Dornan, personal communication, March 
1997) . 
Many researchers believe that the protein beta amyloid, found in 
neuritic plaques, is a primary factor contributing to AD neurodegeneration. 
Neuritic plaques (NP) consist of a central beta amyloid (AB) protein core 
surrounded by a cluster of dystrophic neurites and activated glial cells. 
l\Ieurofibrillary tangles (NFT), of wl,ich tau protein is a major constituent, 
are also found consistently in brain regions affected by AD (Cotman and 
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Pike, 1994). The presence of neuritic plaques and neurofibrillary tangles 
are considered a neuropathological characteristic of AD. They are 
quantified at autopsy in order to make a definite diagnosis of AD. 
However, the criteria used for diagnosis with regards to location and 
quantity neuritic plaques and neurofibrillary tangles vary (Tierney, 1988). 
Results from histological studies of beta amyloid have been 
consistent with the cholinergic hypothesis of AD discussed above. An in 
vivo study by Harknay, Jong et al. (1995) injected beta amyloid (1-42) 
into the medial septal area of rats and found that beta amyloid is 
selectively toxic to cholinergic neurons. GABAergic neurons, also at the 
injection site, showed only minor effects. GABAergic neurons in the 
medial septal area did exhibit some neuritic pruning following beta 
amyloid exposure, a neuronal reaction also observed in AD patients 
(Robakis, 1994). 
Additional in vivo experiments involve beta amyloid injections into 
the nucleus basalis magnocellularis, ~Iippocampus, or ventricles. 
Histological results of these studies are again consistent with the 
cholinergic hypothesis showing reduced acetylcholine release and reduced 
cll0line acetyltransferase and cholinesterase activity in the neural region 
exposed to beta amyloid when compared to controls (Abe, Casamenti, 
Giovannelli, Scali, Pepeu, 1994; Chen, Harding, Barnes, 1996; Dornan, 
Tinkler, Litwiller, Fan, Hanin, at press; Harknay, Lengyel et al.,1995; Itoh, 
Nitta et aI., 1996; Maurice, Lockhart, Privat, 1995; Nitta, Itoh, Hasegawa, 
Nabeshima, 1994). Reduced acetylcholine release as well as reduced 
choline acetyltransferase and cholinesterase activity indicate 
degeneration of cholinergic terminals resulting from neurotoxic effects 
induced by beta amyloid. However, one study by Sigurdsson, Hejna, Lee, 
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and Lorens (1996) did not find that beta amyloid injections produced 
histological signs of toxicity in cholinergic neurons. 
While histological results of beta amyloid testing are fairly 
consistent, behavioral results in studies of the cholinergic hypothesis do 
not yield the same consistency. Among the studies cited above that 
included animal behavioral testing, only three showed significant learning 
impairment (Itoh et aI., 1996; Maurice et aI., 1995; Nitta et aI., 1994). The 
study by Dornan et al. (in press) resulted in only a marginal effect on 
spatial learning following beta amyloid injections, and the Sigurdsson et 
al. (1996) study did not find any behavioral affects. These studies 
indicate degeneration of cholinergic neurons following beta amyloid 
injection without also yielding the cognitive/learning impairments 
associated with AD. This suggests that the degeneration of cholinergic 
neurons may not be responsible for the clinical effects of AD and that the 
cholinergic hypothesis is either insufficient or incorrect. 
The relationship between the severity of AD dementia and' the 
quantity of neuritic plaques and neurofibrillary tangles in the brain is now 
being questioned as well. A study by Snowdon et al. in 1997, know as the 
"1\Jun Study" (the participants were all from The School of Sisters of the 
Notre Dame congregation), found that among women who met the 
neuropathological criteria for AD in terms of the number of neuritic 
plaques and neurofibrillary tangles in the brain at autopsy, 31 % did not 
have prevalent dementia in life based on cognitive testing (Snowdon et aI., 
1997). A review by de la Torre states that the density of plaque and 
tangle formation in nondemented individuals increases as a 'function of 
age, and neuritic plaques and neuro'fibrillary tangles may be found in 100% 
of nondemented persons over 80 years old (de la Torre, 1997). The report 
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goes on to suggest that neuritic plaques and neurofibrillary tangles are 
products of a neurodegenerative process associated with both AD and also 
with normal aging to a lesser extent. 
Based on the studies discussed above, a fresh look at the possible 
risk factors involved in AD development seems warranted. History of 
cardiovascular disease, stroke, or head trauma have all been implicated as 
risk factors (de la Torre, 1997). Also, a genetic/familial link has been 
found with late-onset AD. Mutations at 3 genes have been identified as AD 
risk factors: 1) beta-amyloid precursor protein (APP), 2) presenilin-2 
(PS2) gene, and 3) prensenilin-1 (PS1) gene (Lendon, Ashall, and Goate, 
1997; Prince, Cullen, and Mann, 1994). The PS1 gene mutation is an 
exception to the familial late-onset generalization; the mean age of onset 
associated with PS1 is 46.8 years (Lopera et aL, 1997). In addition, the 
apopliprotein E4 allele (apoE 4) has been linked to AD (Evans et aL, 1997; 
Gordon, Grauer, Genis, Sehayek, and Michaelson, 1995; Kosunen et aL, 
1995; Poirier et aL, 1993). 
Apolipoprotein E is a plasma protein that binds to the low-density 
lipoprotein (LDL) receptor. Lipoproteins are plasma proteins involved in 
transport of cholesterol and other lipids to and from cells. Low-density 
lipoproteins are rich in cholesterol and are therefore involved in the 
growth, repair, and maintenance of myelin and neuronal membranes 
following injury (Marieb, 1992; Mahley, 1988). By binding with low­
density lipoprotein receptors, apoE acts to clear low-density lipoproteins 
from their binding sites. This redistributes the lipoproteins into the 
blood stream (Mahaley, 1988). ApoE mRNA plays an important role during 
central nervous system (CNS) sprouting and synaptogenesis. Messenger 
RNA is reduced in the hippocampus of AD patients, and in apoE deficient 
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mice hippocampal synapse density is reduced (Poirier, Davignon, et aI., 
1993). These mice also have diminished ability to regenerate synaptic 
connections following lesions to the hippocampus. 
There are three apoE alleles (E2, E3, and E4) resulting in six apoE 
genotypes (E2/E2, E2/E3, E3/E3, E3/E4, and E4/E4). Of the apoE alleles, 
E2 has the lowest affinity or the low-density lipoprotein receptor, 
whereas E4 clears this receptor the most efficiently (Mahley, 1988). 
However, efficient clearing of cholesterol by apoE 4 could result in poor 
neuronal reinnervation following injury. Cells rely on cholesterol to build 
up membranes, and apoE 4 clears away needed cholesterol from the 
receptor too quickly for membrane rebuilding to occur satisfactorily. 
Thus, while apoE 4 may clear cholesterol most efficiently, it is also the 
least efficient in aiding reinnervation following trauma to the brain. 
At the same time, because apoE 4 releases the high cholesterol 
lipoprotein from receptors and back in to the bloodstream at a higher rate, 
it causes an increase in plasma cholesterol. Increased cholesterol levels 
have been implicated in the development of atherosclerosis. 
Atherosclerosis is a thickening of the atrial walls causing them to 
protrude into the vessel lumen and possibly occlude the vessel entirely 
(Marieb, 1992). 
The "response-to-injury" hypothesis is the most commonly accepted 
explanation for atherosclerosis development. This hypothesis states that 
an initial event occurs which causes damage to the tunica intima., the 
endotllelial layer lining blood vessels. An initial event can be brought on 
by blood borne cllemicals, viruses, or physical factors such a blow to the 
head or hypertension. Injured endothelial cells of the tunica intima 
release chemotactic agents, and growth factors begin to transport greater 
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amounts of cholesterol picked up from the blood in an effort to repair cell 
damage. (This involves apoE, and apoE has been shown to upregulate in 
response to injury (Hall, Oostveen, Dunn, and Carter, 1995).) Monocytes 
cling to the sites of altered endothelial cells and then migrate beneath the 
surface of the tunica intima where they become macrophages. Tllese 
macrophages are joined by smooth muscle cells which begin moving 
toward the intima layer from the tunica media. Both smooth muscle cells 
and macrophages begin accumulating cholesterol and take on the 
appearance of foam cells - the "fatty streak stage." It is at this stage 
that the excess plasma cholesterol resulting from apoE 4 is most 
detrimental (Marieb, 1992). 
Muscle cells at the intima also deposit collagen and elastin fibers. 
These fibers thicken and harden the tunica intima producing lesions ­
atherosclerotic plaques. When fatty mounds of muscle and fibrous tissue 
begin to protrude into the lumen of the blood vessel, the individual has 
full-blown atherosclerosis. Eventually, arterial walls become frayed and 
ulcerated. These conditions encourage platlet adhesion and thrombus 
formation. Increased vessel rigidity leads to hypertension, increased risk 
of myocardial infarction, stroke, and aneurysm (Marieb, 1992). 
Damage to blood vessels when apoE 4 is present might also lead to 
an increase in beta amyloid deposition along arterial walls. A study done 
by Hall et al. (1995) induced ischemic trauma for 10 minutes in the 
forebrains of gerbils. Beta amyloid protein and apoE activities were then 
followed in the ~Iippocampus over a period of 7 days. After two days, a 
signi'ficant increase in both beta amyloid and apoE was recorded in the 
hippocampus (Hall et aI., 1995). Results of other studies have shown that 
apoE 4 binds to beta amyloid leading to co-deposition of both apoE 4 and 
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beta amyloid at the cell (Strittmatter et aI., 1993; Wizniewski, Golabek, 
Matsuhara, Ghiso, Frangione, 1993). It has been hypothesized that the 
upregulation of apoE in response to ischemic trauma together with the 
binding of apoE 4 and beta amyloid may provide favorable conditions for 
the formation of neuritic amyloid deposits. In additional studies, apoE 4 
is associated with reduced cerebral glucose metabolism. This can lead to 
improper splitting of beta amyloid and, therefore, an increase in neuritic 
plaque formation (Mier-Ruge, Bertoni-Freddari, Iwangoff, 1994). 
In his review article, de la Torre lists four primary changes seen in 
the capillary microanatomy of AD patients: 1) thickening of the vessel 
wall and the basement membrane, 2) intraluminal distortions produced by 
kinking or compression of the abluminial region, 3) endothelial cell 
compression with mitochondrial loss, and 4) amyloid deposition in vessel 
walls. Atherosclerosis pathology can lead to all four of these changes. 
Additionally, beta amyloid deposited along vessel walls interferes with 
the exchange of nutrients and wastes between capillaries and cells, 'and 
distorted lumens result in a disturbed blood flow pattern, also making 
exchange across the capillaries difficult. As mentioned above, reduction 
of oxygen and nutrients reaching the cells can lead to necrosis (cell death) 
as well as the build up of beta amyloid in cells resulting from a shortage 
of ATP necessary to properly split the beta-amyloid precursor protein 
(Mier-Ruge, Bertoni-Freddari, Iwangoff, 1994). 
In a clinical study done by Hoffman et al. (1997), the frequency of AD 
and of vascular dementia was found to increase with the degree of 
atherosclerosis (mild, moderate, severe). In the conclusion of this study, 
it is stated that dementia, and in particular dementia of the AD and the 
vascular type, is associated with atherosclerosis. It is also concluded 
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that there is an interaction found in AD etiology between apoE and 
atherosclerosis (Hoffman et aI., 1997). Another clinical study, this one by 
Kosunen et al. (1995), concluded that the apoE 4 allele is associated with 
coronary atherosclerosis in elderly AD patients. This study also states a 
lack of associative findings between the extent of coronary or cerebral 
atherosclerosis and counts of neuritic plaques. The study by Kosunen 
reinforces the Nun Study, which found that neuritic plaques sufficient for 
AD diagnosis did not necessarily coincide with AD dementia. Such 
findings lead to questions about the role of neuritic plaques in AD 
dementia just as animal tests investigating the role of acetylcholine in 
AD dementia have brought the cholinergic hypothesis into question. 
New avenues must be explored for risk factors in AD. 
Atherosclerosis is found in association with several forms of dementia 
and a study of the relationship between severity of atherosclerosis and 
severity of AD dementia, regardless of the number of neuritic plaques 
found is warranted. This study assesses the severity of AD dementia in 
relation to severity of atherosclerosis in AD patients as well as the age 
of AD dementia onset when AD is found in association with 
atherosclerosis with the expectations that as severity of atherosclerosis 
increases, so does AD severity and that AD onset will be earlier when 
associated with atherosclerosis. 
Methods 
Participants 
Alzheimer's disease can only be definitively diagnosed by 
postmortem examination of the brain; therefore, autopsy examination of 
participants at death is an integral part of this investigation, and brains 
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are procured from all participants who remain in the study. Consent for 
this procedure is given by legal next-of-kin upon entry into the study, and 
results from the brain autopsy are provided to the family free of charge. 
The present study is part of an ongoing research project beginning in 
1996, and twenty-five participants are currently enrolled in this study. 
Eight are now deceased, and autopsy information is available for seven of 
these. Participants may withdraw from the study any time they wish. 
This study is being conducted primarily in central Illinois, and, 
therefore, the majority of the participants live in that area. Overviews of 
the IWU brain donor program are given primarily at area hospitals, 
schools, nursing homes, etc. As a result, contact regarding participation 
is generally initiated by the family members of those diagnosed with 
possible or probable Alzheimer's dementia who have attended these talks. 
This also means that participants are diagnosed outside of the study by 
primary care physicians or neurologists. Many of the participants referred 
to this program are nursing home residents although some do still live at 
home. 
Apparatus and Procedure 
Several assessments of daily living (ADL's) scales as well as 
cognitive tests are given to all participants upon entry into the study. In 
addition, care givers are be asked to provide demographic information 
about participants, medical histories are gathered, and participants are 
assessed by a neuropsychologist for possible depressive disorders (which 
may skew cognitive data if present). Testing is split into two sessions, 
separated by a few days, and tests are administered where the participant 
resides, at the home or in a nursing home. The ADL's and cognitive tests 
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are re administered every six months. Cognitive testing may be dropped if 
the participant has progressed to severe dementia and is no longer able to 
complete these tests, but ADL's are still assessed. 
During the first session, ADL's will be filled out by either the 
primary investigator (PI) or research assistants with the help of a care 
giver, professional or family. The participant is not required to be 
present at this time, particularly if discussion about progressing 
dementia and declining skill becomes upsetting. In all, seven ADL's are 
given, the Barthel ADL Index, the Brief Cognitive Rating Scale (BCRS), the 
Blessed Dementia Scale, the Clinical Dementia Rating (CDR Staging), the 
Functional Assessment Staging (FAST), the Global Deterioration Scale 
(GDS), and the Modified Rankin Scale (Blessed, G., Tomlinson, B., Roth, M., 
1968; Chino, N., Melvin, J., 1996; Haycox, J., 1984; Reisberg, B., 1988; 
Reisberg, B., Ferris, S., de Leon, M., Crook, 1., 1982; Reisburg, B., Schneck, 
M., Ferris, S., Schwartz, G., de Leon, M., 1983; Mahoney, R., Barthel, D., 
1965). Also, the Hachinski Ischemic Score is determined by the Pi in 
consultation with the primary physician or with medical history 
(Hachinski, V., IIkff , L., Zilkha, E., 1957). The Hachinski is used to 
determine whether or not the patient has had any transient ischemic 
attacks in the past. 
After the ADL's have been 'filled out, the Mini-Mental State 
Examination (MMSE) is administered (Folstein, M. Folstein, S., McHugh, P., 
1975). Cognitive tests are administered by either the PI or by research 
assistants trained by neuropsychologists at Bromenn Regional Medical 
Center. Participants are told tl1at tl1ey will be asked questions to test 
their memory. They are instructed that some of these questions are 
harder than others and that they are not expected to answer them all 
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correctly. Participants are then be asked if they agree to answer these 
questions. If they respond "yes," they are further instructed that the test 
may be halted at any time upon their request. MMSE testing lasts 
approximately ten minutes. If a participant becomes frustrated with a 
question, the researcher moves on to the next question, and if the 
participant is unable to complete the test, the reason is noted on the test 
sheet and the maximum incorrect score is given for questions not 
answered. Out of a total of thirty points, a score equal to or greater than 
twenty-four indicates very mild dementia, a score equal to or greater than 
twenty indicates mild dementia, a score of between ten and nineteen 
indicates moderate dementia, and a score between zero and nine indicates 
severe dementia. 
Participants who score in the mild to moderate dementia range 011 
the MMSE are scheduled for a second test. This is generally scheduled 
within a few days or weeks. The Alzheimer's Disease Assessment Scale 
(ADAS) is the second cognitive test given, and it is the most widely known 
and commonly accepted cognitive test for assessing AD (Mohs, R., Rosen, 
W., Davis, K., 1983). On the ADAS, a score of 0-5 is perfect (no dementia), 
6-10 is average, 11-23 is mild, 24-35 is moderate, 36-49 is severe, and 
50-70 is very severe. Because the ADAS is a longer and more complicated 
test, if a participant scores in the severe dementia range on the MMSE, the 
ADAS is not administered. Test instructions given to the participant and 
scoring procedures for a discontinued test are the same as above. Again, 
these tests are administered in either the participant's residence or 
nursing home by the PI or by research assistants. The ADAS takes 
approximately thirty minutes to complete. 
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At the time of death, either the nursing home or the family of the 
participant will contact the funeral home of the family's choice, the 
McLean County Coroner's Office, and the PI. Arrangements are then made 
for brain procurement. The funeral home generally transports the body to 
the McLean County Morgue, and brain procurement takes place no longer 
than six hours of death with the PI in attendance. Research assistants 
may also be present. 
In addition to brain procurement, an initial assessment also takes 
place at the McLean County Morgue. The brain is then taken to the Loyola 
University School of Medicine where autopsy is performed. The brain is 
cut serially in a coronal fashion using a microtome. Sections one 
centimeter square are fixed in paraffin to be later stained using Multiple 
Luxol Fast Blue/H & E and also Bielschowsky silver. These stains are used 
for diagnostic purposes to reveal amyloid plaques, both diffuse and 
neuritic, in the cerebral cortex. A cryostat is also used to cut smaller 
sections of brain (40 microns) which will be frozen and used in future 
analysis. 
Analysis 
Blind to the autopsy results, participant data is separated into 
groups based on medical l"Iistory as well as cognitive and functional test 
scores. Data is separated into two groups, probable AD in the absence of 
atherosclerosis or probable AD with atherosclerosis. Once participant 
records have been sorted into groups, researcl1er accuracy is tested by 
comparing these groups to autopsy reports. 
Due to the as of yet small sample size (seven completed autopsy 
reports), meaningful statistical analysis is not possible. Instead, a case 
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study for each participant with an autopsy report available has been 
written. Demographic data, medical history, cognitive test scores, and 
final autopsy analysis is included. Qualitative analysis based on these 
seven cases has been conducted. 
Resu Its 
Case One 
This 86 year old white male (12/05/09 - 10/07/96) presented with 
memory problems that were becoming gradually worse in August of 1991 
(at age 81). Based on a physical workup and an MMSE score in the 
moderate to severe range, a preliminary diagnosis of probable AD was 
made. Medical history indicates a recovery from cancer several years 
prior. 
Patient had 12 years of education and worked as a general yard 
master for an oil refinery until his retirement at age 65. For the last 20 
years of his life, he lived in a rural, nonfarm, geographic area. In 1996, he 
moved into a nursing home. The patient was married at the time of his 
death. 
When he was diagnosed, the patient was not oriented to date or 
month. He could not spell "train" backwards; however, he could spell 
"box" backwards. Six months following the initial assessment, the 
patient began to show signs of language impairment. "[The patient] seems 
to search for words and has trouble finishing a thought." His language 
ability continued to deteriorate over the next few months. At this point, 
January 1993, the patient gave up driving. 
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In December of 1993, this patient was started on Cognex, a drug 
developed to help combat dementia. Five months later, the family 
reported noted improvements in the patient's cognition and the dosage 
was increased. However, a few months later family reported resumed 
cognitive deterioration. The patient continued on Cognex until April of 
1995, including another dosage increase in January of that same year. 
Until April of 1995, the patient's ability to care for himself, home 
hygiene and dressing, remained relatively stable. If his clothes were laid 
out for him, he could dress himself. By the spring of 1995, however, he 
could no longer dress himself. His language abilities had also deteriorated 
to "yes" or "no" responses in reply to questions asked of him. Patient 
was described as "very confused." Later, that year the patient began 
"sun-downing," this is when the sleep-wake cycle is disrupted. He would 
awaken in the evenings. 
Between April, 1996 and June, 1996, patient was prescribed Haldol, 
an antipsychotic, for severe agitation. The patient was admitted to' the 
hospital in June of 1996 with a fractured hip. Evidence of marked 
arteriosclerosis, a vascular disease, was also noted at this time. The 
patient died in October of this same year. Before his death, the patient's 
dementia had progressed to the severe level, with a score of 0/30 on the 
MMSE. He had lost all verbal abilities and was incontinent. 
Brain procurement took place October 7, 1996, and the brain was 
taken to Loyola that same day. The brain weighed 1039 grams. Gross 
examination revealed mild focal atherosclerotic plaque in the internal 
carotid arteries. Mild to moderate atrophy was observed throughout the 
cerebral cortex. The amygdala was moderately atrophic bilaterally, while 
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the hippocampus showed moderate atrophy on the left and severe atrophy 
on the right. 
Microscopic examination showed numerous amyloid plaques, both 
neuritic and diffuse, and neurofibrillary tangles in all cerebral cortical 
areas as well as the amygdala and hippocampus. Tables of the 
microscopic neuritic plaque and neurofibrillary tangle findings with 
respect to location in the brain for all 7 participants are below (Table One 
and Table Two). Final diagnosis for this patient was severe AD, mild 
arteriosclerosis, and mild cerebral amyloid angiopathy of the cerebral 
cortical and leptomeningial (supply to the hippocampus) blood vessels. 
Case Two 
T~lis 73 year old white male (8/27/24 - 8/23/97) presented with 
confusion, memory problems, and increasing agitation beginning in about 
1992, at age 68. He was brought to a physician in April of 1994 and a 
preliminary diagnosis of AD or agitated depression was made. During the 
following month, after a series of tests, depression was ruled out and a 
diagnosis of probable AD was given. 
Patient had 16 years of education and worked as an undertaker for 
about 35 years. For the last 20 years of his life, he lived in a small city 
geographic area (50,000-200,000 population). In 1996 he moved into a 
nursing home. The patient was married at the time of his death. 
When he was diagnosed, the patient was slightly unkept in 
appearance and was not performing hygiene activities adequately. He was 
disoriented to time, place, and date, and he was unable to give his date of 
birth or address. He also could not name his two children. The patient's 
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speech was clear; however, he did not speak in full sentences, and he 
spoke only when asked direct questions. He had difficulty initiating his 
thought and verbalization process. Patient denied any difficulty with 
memory, activities, or behavior. 
A computer topography (CT) was conducted in April 1994. 
Hemorrhage in the right lateral ventricle was noted and a right 
intracranial shunt tube was seen. Overall, no abnormality was identified. 
Haldol was prescribed in June of 1994 for agitation. The prescription was 
later discontinued in September, 1996, one month before admission into a 
nursing home. 
Patient's level of ability in activities of daily living continued to 
decline throughout his stay in the nursing home. Two months before his 
death, he required feeding from staff, was incontinent, was unable to 
dress himself or find his way to his room, could not walk without 
assistance, and his speech was unintelligible. Before his death, this 
patient's dementia had progressed to the severe level with a score of 
0/30 on the MMSE. 
Brain procurement took place August 23, 1997, and the brain was 
taken to Loyola that week. The brain weighed 1187 grams. Gross 
examination revealed no evidence of atherosclerosis in the intra cranial 
blood vessels. Mild to moderate atrophy throughout the cerebral cortex 
was observed. The amygdala was moderately to severely atrophic 
bilaterally, and the hippocampus was moderately atrophic bilaterally. 
Microscopic examination revealed numerous diffuse and neuritic 
amyloid plaques and neurofibrillary tangles throughout the cerebral 
cortex, hippocampus, and amygdala. (See Table One and Table Two below.) 
Additionally, neuronal loss was observed predominantly in the temporal 
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lobe. Final diagnosis for this patient was severe AD, and mild focal 
cerebral amyloid angiopathy. 
Case Three 
This 76 year old white female (1/03/21 - 3/05/97) presented with 
memory problems that were gradually worsening in June of 1996. The 
patient had a history of clinical depression, seizures, and she had 
experienced head injury with loss of consciousness in a train accident 47 
years earlier (1943). Depression was ruled out as the cause of dementia, 
and the patient was admitted to a nursing home. 
Patient had 12 years of education, and she worked as a nurses' aid 
until her retirement in 1989 at age 68. For the last 20 years of her life, 
she lived in a rural, nonfarm, geographic area. Patient was never married. 
Her family history indicates a brother with memory problems. Both 
parents died of heart failure; however, they were well into their 90'.s at 
the time of death. 
During her stay in the nursing home, the patient was on Haldol and 
Prozac (and antidepressant). At the time of her death, the patient was 
incontinent, had to be bathed and fed, could not find her way to her room, 
and was unable to dress herself. She also had progressed into the severe 
range of dementia, scoring 0/30 on the MMSE. 
Brain procurement took place March 5, 1997, and the brain was taken 
to Loyola that same day. The brain weighed 1270 grams. Gross 
examination revealed mild atherosclerotic plaque in the internal carotids 
and basilar arteries as well as the left vertebral artery. No gross 
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abnormality was observed in the cerebral cortex. Both the amygdala and 
hippocampus were also unremarkable at gross examination. 
Microscopic analysis revealed numerous amyloid plaques, diffuse and 
neuritic, throughout all cerebral cortical areas. Neurofibrillary tangles 
were found primarily in the temporal lobe. The amygdala and hippocampus 
both had numerous neuritic plaques and neurofibrillary tangles. (See Table 
One and Table Two below.) Final diagnosis for this patient was moderate 
to severe AD and mild atherosclerosis involving the internal carotids, 
basilar, and vertebral arteries. 
Case Four 
This 85 year old wh ite female (12/01/11 - 4/05/97) began 
suffering from gradually worsening dementia in July of 1992. She had a 
history of depression, but this was ruled out as the cause of dementia. 
The patient also had a history of cancer, arthritis and cataracts. 
Patient had over 12 years of education, and she worked as a 
secretary until she retired in 1968 at 57 years of age. For the last 20 
years of her life, she lived in a small city geographic area (50,000­
200,000 population). Family history indicates a paternal aunt with 
suspected AD. Patient's social history shows that she was a smoker for 
20-30 years, <1/2 pack per day. 
At the time she entered into the study, this patient was unable to 
feed or dress herself, was occasionally incontinent, and could not find her 
way to her room. The patient was also showing bellavioral changes, but 
she was not taking any medications. 
One week after being admitted into the nursing home, patient 
became severely dehydrated and had to be hospitalized. The patient 
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passed away later that week. She had progressed to severe dementia, 
scoring 0/30 on the MMSE. 
Brain procurement took place April 5, 1997, and the brain was taken 
to Loyola that day. The brain weighed 920 grams. Gross examination 
showed moderate atherosclerotic plaque of the internal carotids and mild 
atherosclerotic plaque of the Circle of Willis and the middle cerebral 
arteries. Moderate to severe generalized atrophy of the cerebral cortex 
was observed. In the temporal lobe, atrophy on the left was more severe 
that the right. Mild to moderate atrophy of the amygdala and severe 
atrophy of the hippocampus bilaterally were also observed. 
Microscopic analysis revealed numerous amyloid plaques, diffuse and 
neuritic, and neurofibrillary tangles in all cerebral cortical areas. 
Hippocampus examination showed numerous neurofibrillary tangles and 
neuritic plaques as did the amygdala. (See Table One and Table Two 
below.) Final diagnosis for this patient was severe AD and mild to 
moderate atherosclerosis involving the internal carotids and middle 
cerebral arteries as well as the Circle of Willis. 
Case Five 
This 84 year old white male (6/30/12 - 2/24/97) presented with 
memory problems in April of 1986 at the age of 83. The onset of major 
symptoms was gradual and impairment became gradually worse. Four 
years later, he was admitted to a nursing home with a diagnosis of 
probable AD, Parkinson's, angina, and probable transient ischemic attacks. 
Patient had 8 years of education, and he was a farmer for most of 
his life until retirement. For the last 20 years of his life, the patient 
lived in a rural, farm, geographic area. He was married at the time of his 
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death. Family history does not indicate any family members with memory 
problems; however, his eldest brother had Parkinson's disease. 
At the time he was admitted into the nursing home, this patient was 
exhibiting language impairment, behavioral changes, and disorientation to 
time and place. Over the course of the disease, he became incontinent, 
unable to feed or clothe himself, and unable to find his way to his room. 
By June of 1993, he was totally dependent for all care. 
After being admitted into a nursing home, the patient began physical 
tllerapy w~lich included gait training to improve posture, and balance. 
Patient was prescribed Carbidopa for his Parkinsonian symptoms in May, 
1996. This drug appeared to decrease tremors. Episodes of apnea were 
observed in October, 1996. By the time of his death, the patient had 
progressed to severe dementia, scoring 0/30 on the MMSE. 
Brain procurement took place February 2, 1997, and the brain was 
taken to Loyola the following day. The brain weighted 970 grams. Gross 
examination revealed moderate to severe atherosclerosis, involving' the 
internal carotids, middle and posterior cerebral, and basilar arteries. 
Anterior cerebral and vertebral arteries had mild atherosclerotic plaque. 
Mild to moderate atrophy of the cerebral cortex was observed. Both the 
hippocampus and the amygdala were severely atrophic bilaterally. 
Microscopic examination revealed numerous amyloid plaques, diffuse 
and neuritic, throughout the cerebral cortex. Many neurofibrillary tangles 
were noted as well. The temporal lobe was most affected. It contained 
many neuritic plaques and neurofibrillary tangles. (See Table One and 
Table Two below.) Final diagnosis for this patient was severe AD, 
moderate to severe cerebral amyloid angiopathy, severe arteriosclerosis, 
moderate to severe atherosclerosis, and micro infarction of the remote 
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right 'frontal/orbital surface. No pathological evidence for Parkinson's 
disease was found. Parkinson-like symptoms were probably due to the 
severity of AD combined with vascular disease. 
Case Six 
This 81 year old white female (1/22/16 - 5/10/97) was found lying 
on the floor by a neighbor on August 19, 1994 and was subsequently 
110spitalized. She had been experiencing memory problems for the past 
several years, beginning at approximately age 78. She had a history of 
transient ischemic attacks as revealed by her medical charts. Also, a 
1992 carotid Doppler revealed 70-75% stenosis of the left carotid, and 
she had a pacemaker. 
Patient had 14 years of education, and she worked as a teacher for 
some years before becoming a housewife. For the last 20 years of her 
life, she lived in a rural, farm, geographic area. She was admitted into a 
nursing home in September of 1994. At the time of her death, the patient 
was widowed. 
While she was in the nursing home, the patient experienced 
increasing tearfulness, and she was placed on Pazil, an antidepressant. 
She was diagnosed as having a recurrent major depressive disorder. Her 
cognitive abilities continued to deteriorate, and she experienced episodes 
of confusion. A diagnosis of probable AD was made. The patient was still 
able to recognize her daughter and her surroundings. She was also 
ambulatory and could find her way around the nursing home although 
episodes of wandering off the premises were noted. She was not oriented 
to date and time, and she required assistance in most of her activities of 
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daily living but was not totally dependent. At the time of her death, the 
patient had progressed to severe dementia, scoring 3/30 on the MMSE. 
Brain procurement took place May 13, 1997, and the brain was taken 
to Loyola the same day. The brain weighed 970 grams. Gross examination 
revealed mild to moderate atherosclerosis in the internal carotids, 
basilar, and vertebral arteries. Mild atherosclerotic plaque was noted in 
the anterior, middle, and posterior cerebral arteries and the Circle of 
Willis. Mild generalized atrophy was observed throughout the cerebral 
cortex. The amygdala was mildly atrophic, and the hippocampus was 
moderately atrophic bilaterally. 
Microscopic examination revealed numerous amyloid plaques 
throughout the cerebral cortex, mostly of the diffuse type. However, the 
temporal lobe revealed numerous neuritic plaques and neurofibrillary 
tangles. Neurofibrillary tangles were noted scattered in the frontal and 
parietal lobes as well. Numerous neuritic plaques and neurofibrillary 
tangles were observed in both the amygdala and hippocampus. Final 
diagnosis for the patient was moderate AD, focal cerebral amyloid 
angiopathy involving leptomeningeal vessels, and mild to moderate 
atherosclerosis. 
Case Seven 
This 89 year old white female (10/19/17 - 12/13/96) began 
presenting gradual onset memory problems in the early spring of 1974 at 
the age of 66. These memory problems were becoming gradually worse 
although the patient denied confusion. Her medical history indicates heart 
disease hypertension, angina, and seizures. Early examinations in 1977 
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resulted in a diagnosis of probable early dementia. By 1985 the diagnosis 
had become probable AD. 
Patient had 8 years of education, and she was a housewife. For the 
last 20 years of her life she lived in a small city (50,000-200,000 
population) geographic area. In 1985, she was admitted into adult 
daycare, and by 1986, she was in long-term care. At the time of her 
death, the patient was widowed. Family history indicates that her mother 
died of a stroke and her father died after a heart attack. 
In 1985, the patient began a prescription of Haldol for agitation. 
She experienced episodes of confusion and disorientation to her 
surroundings. At this time, she was also prescribed Inderal and Digoxen 
for her heart. A CT revealed cortical atrophy, and a later abdominal series 
in 1986 revealed evidence of arteriosclerotic vascular disease. 
In 1986, after being admitted into long-term care, the patient 
experienced much confusion and disorientation. She could not understand 
where she was and why she could not go home. Her language abilities 
continued to deteriorate until she could no longer "make her wants or 
needs known," 1994. She remained ambulatory until 1995. Even then, she 
could walk a few steps with assistance. She was however, totally 
dependent in her activities of daily living. She was unable to feed and 
dress herself or find her way to her room, and she was also incontinent. 
By her death, the patient had progressed to severe dementia, scoring a 
1/30 on the MMSE. 
Brain procurement took place December 13, 1996, and the brain was 
taken to Loyola the same day. The brain weighed 720 grams. Gross 
examination revealed moderate atherosclerotic plaque in the internal 
carotids, middle and posterior cerebral, basilar, and vertebral arteries. 
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Mild generalized atrophy was observed in all cerebral cortical areas. The 
amygdala was mildly atrophic bilaterally, and the hippocampus showed 
moderate to severe atrophy bilaterally. 
Microscopic examination revealed numerous amyloid plaques, diffuse 
and neuritic, and neurofibrillary tangles throughout all cerebral cortica.l 
areas. The amygdala showed numerous neurofibrillary tangles, and 
hippocampal examination revealed numerous neuritic plaques and 
neurofibrillary tangles. (See Table One and Table Two below.) Final 
diagnosis for this patient was severe AD, Parkinson's, moderate to severe 
arteriosclerosis, and moderate atherosclerosis involving the internal 
carotids, middle and posterior cerebral, basilar, and vertebral arteries. 
Table One- Number of Amyloid Plaques (Neuritic Plaques) for Patients 
One-Seven 
Patient: 
Area 
One Two Three Four Five Six Seven 
Premotor: 10 (5) 18 (14) 22 (1) 7 (4) 12 (5) N/A N/A 
Frontal: >30 (>3) N/A >30 (>3) 36 (7) 20 (16) N/A 20 (16) 
Temporal: 15 (6) >30 (24) 25 (6) 20 (12) 20 (18) N/A >30 
(>27) 
Parietal: 8 (6) >30 (>9) 10 (3) 28 (6) 20 (4) N/A >30 (>6) 
Occipital: 14 (11) 10 (8) 8 (1) 12 (10) 18 (16) N/A 10 (8) 
Amygdala 10 (8) 22 (20) 15 (11) 8 (6) N/A N/A 12 (10) 
Number of amyloid plaques per brain region in bold, number of 
amyloid plaques which are neuritic in parentheses. (200x Magni'fication) 
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One
 
able umb 0 N fbn'IIary ang es for Palents ane-Seven 
Patient: 
Area 
Premotor: 
Frontal: 
Temporal: 
Parietal: 
Occipital: 
Amygdala 
2 
22 
36 
28 
8 
24 
Two 
8 
Three 
0 
Four 
2 
Five 
8 
Six 
N/A 
Seven 
N/A 
N/A 0 18 23 N/A 46 
>20 7 26 >40 N/A 32 
13 1 10 22 N/A 24 
6 0 12 3 N/A 3 
>30 3 16 N/A N/A 8 
Number of neurofibrillary tangles per brain region. (200x 
Magnification) 
The largest number of amyloid plaques among members of this group 
appear in the temporal lobe. The frontal and parietal lobes are not far 
behind. When taking into account the number of these which are neuritic, 
the temporal lobe continues to have the highest number (93). The frontal 
lobe (45) again comes in second, along with the amygdala (55) and the 
occipital lobe (54), although these are not as close in number to the 
temporal lobe as they were when considering the number of plaques 
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overall. The parietal does not have a high number of neuritic plaques (34), 
comparatively, even though it was among the top brain regions when 
considering the number of amyloid plaques. The premotor cortex has a low 
number of both amyloid plaques and neuritic plaques (29). 
With the exception of Patient Two, the brain region with the most 
neurofibrillary tangles is the temporal lobe in all patients. Patient Two 
has the largest number of neurofibrillary tangles in the amygdala. It 
should be pointed out that Patient Two presented with increasing 
agitation as part of AD onset. He was also on a prescription of Haldol for 
two years. 
Average adult brain weight is 1250 grams (V. Hnilika, personal 
communication, April 1998). Atrophy, reported in the case studies above, 
decreases brain weight. Table Three shows brain weights at autopsy for 
each of the seven patients and the amount of difference between this 
weight and average adult brain weight. In addition, Table Three lists the 
duration of the disease. 
Table Three- Duration of AD for Each Patient in Comparison to Decrease 
B . W' ht I f W . ht fIn rain elg , n erre d from DeVlance In elg rom Average AduIt 
One 
1039 gm 
Patient:
 
Brain
 
(grn):
 
Difference
 
(gm):
 
Duration:
 
211 gm
 
5 years 
Two Three Four Five Six Seven 
1187gm 1270 gm 920gm 970gm 970gm nOgm 
63 gm Not 
applicable 
330gm 280gm 280gm 530gm 
6 years 1 year 5 years 1 year 3 years 23 years 
Difference in patient brain weight from average adult in relation to 
duration of illness. 
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In addition to being analyzed in relation to brain weight, duration of 
illness has been analyzed in relation to cognitive test scores and 
activities of daily living functional scores. All of the seven patients in 
this study were too severely demented to take the ADAS cognitive test; 
therefore, only the MMSE was given. On the MMSE, 30 is the maximum 
correct score. Patients are scored by the number correct out of 30. 
Activity of daily living assessments are also included in Table Four. On 
the Barthel, maximum severity is a score of 0 on a scale of 20. For the 
remainder of the activities of daily living assessments, a maximum score 
equates to maximum severity (i.e. the higher the score the more severe the 
impairment) . 
Table Four- Cognitive Test and Activity of Daily Living Scores in 
Relation to Duration of Illness for Each Patient 
Patient: One Two Three Four Five Six Seven 
Duration: 5 years 6 years 1 year 5 years 1 year 3 years 23 years 
MMSE: 0/30 0/30 0/30 0/30 0/30 3/30 1130 
Barthel: N/A 6/20 N/A N/A N/A N/A N/A 
FAST: 7b17f 7c17f N/A 6a17f 7f17f N/A N/A 
Blessed: N/A 15/17 17/17 N/A N/A N/A 16/17 
Rankin: N/A 4/5 N/A N/A N/A N/A N/A 
aDS: 717 717 N/A 617 417 N/A N/A 
As discussed in Methods, this researcher separated patients into 
two groups - probable AD with atherosclerosis and probable AD without 
atherosclerosis - while still blind to autopsy results. This assessment 
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was done without any medical training and based solely on available 
medical records/histories as well as cognitive and functional test scores. 
Assessment was 57% accurate. Research assessment in relation to 
autopsy assessment is shown below in Table Five. 
Table Five- Assessment of Research Diagnosis of Patients One-Seven in 
R I ' A t D'lagnoslse atlon to u opsy 
Patients: One Two Three Four Five Six Seven 
AD at 
Autopsy: 
Yes Yes Yes Yes Yes Yes Yes 
Athero­
sclerosis 
at 
Autopsy: 
No No Yes Yes Yes Yes Yes 
Correct! 
Incorrect: 
Incorrect Correct Incorrect Incorrect Correct Correct Correct 
Of the incorrect cases above, Patient Three and Patient Four were 
placed into the AD without atherosclerosis group by this researcher. 
Autopsy results show that Patient Three did in fact have mild 
atherosclerosis present while Patient Four had mild to moderate 
atherosclerosis present. 
Tables Six, Seven, and Eight below deal with the character of AD in 
relation to atherosclerosis. Table Six shows severity of AD in relation to 
severity of atherosclerosis. Table Seven shows patient age at AD onset 
with respect to presence or absence of atherosclerosis, and Table Eight 
shows length of AD duration, between onset and death, with respect to 
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presence or absence of atherosclerosis. Dementia for all patients at the 
time of death was severe, based on cognitive testing. 
Table Six- Severity of AD in Relation to Severity of Atherosclerosis in 
Patients One-Seven 
Patient: One Two Three Four Five Six Seven 
AD 
severity: 
Severe Severe Moderate-
Severe 
Severe Severe Moderate Severe 
Athero- Condition Condition Mild Mild- Moderate- Mild- Moderate 
sclerosis not not Moderate Severe Moderate 
severity: present present 
Table Seven- Age at AD Onset with Respect to the Presence or Absence 
of Atherosclerosis 
Patient: One Two Three Four Five Six Seven 
Age at 
Onset: 
81 67 75 80 83 78 66 
Athero­
sclerosis?: 
No No Yes Yes Yes Yes Yes 
Severity N/A N/A Mild Mild- Moderate- Mild- Moderate 
of Athero- Moderate Severe Moderate 
sclerosis: 
Severity of atherosclerosis, when present, given for reference. 
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Table Eight- Duration of AD with Respect to the Presence or Absence of 
Atherosclerosis 
Patient: One Two Three Four Five Six Seven 
Duration 
ofAD: 
5 years 6 years 1 year 5 years 1 year 3 years 23 years 
Athero­
sclerosis?: 
No No Yes Yes Yes Yes Yes 
Severity N/A N/A Mild Mild- Moderate- Mild- Moderate 
of Athero- Moderate Severe Moderate 
sclerosis: 
Severity of atherosclerosis, when present, given for reference. 
Out of five severe AD cases, atherosclerosis was found in three. Of 
these three, atherosclerosis severity ranged from mild-moderate to 
moderate-severe. Duration of the disease in the moderate-severe case 
was only one year, much shorter than the other two severe AD cases with 
associated atherosclerosis. However, of these two remaining cases, the 
mild-moderate case, Patient 7, had a longer duration than the mild 
atherosclerosis case. Also, the two cases of AD without atherosclerosis 
had similar durations to the AD with mild-moderate atherosclerosis case. 
One final note, four out of seven patients showed cerebral amyloid 
angiopathy at autopsy. This is deposition of beta amyloid along blood 
vessel walls and is consistent with the study by Hall et al. discussed 
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earlier. Table Nine shows the severity of cerebral amyloid angiopathy, if 
present, for all seven patients in relation to severity of AD, age at AD 
onset, and duration of AD. 
a N"me- C braI A I 'd Anglopat Iy In R I ' to ADT ble ere mylol h e atlon 
Patient: 
• 
CAA 
Severity: 
AD 
Severity: 
AD 
Duration: 
Age at AD 
Onset: 
One
 
Mild
 
Severe 
5 years 
81 
Two Three Four Five Six Seven 
Mild Not 
Present 
Not 
Present 
Moderate-
Severe 
. Mild Not 
Present 
Severe Moderate-
Severe 
Severe Severe Moderate Severe 
6 years 1 year 5 years 1 year 3 years 23 years 
67 75 80 83 78 66 
Cerebral Amyloid Angiopathy is abbreviated as (CAA). 
Discussion 
Alzheimer's research has explored many 
the years in search of a cause and ultimately 
avenues 
a cure. 
over 
Two 
the c
such 
ourse of 
avenues 
have been discussed in this paper, the cholinergic hypothesis and the 
hypothesis relating to the quantity of beta amyloid/neuritic plaques 
present in the brain. Behavioral studies of the cholinergic hypothesis 
failed to find learning deficiencies associated with the acetylcholine 
neurotransmitter in rats. These findings cast doubt on the theory that 
lowered acetylcholine levels are the underlying cause of AD dementia. 
With regard to the quantity of neuritic plaques in the brain and their 
association with AD and AD dementia, criteria for the number of neuritic 
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plaques present and in what areas of the brain are not definite. 
Additionally, Snowdon et al.'s "Nun Study" found that a diagnosis of AD 
could be made at autopsy on the basis of neuritic plaque findings without 
any corresponding in-life dementia. 
The present study showed a wide number range of neuritic plaques 
in those diagnosed with severe AD (39-75 neuritic plaques), and only as 
little as 25 neuritic plaques were needed for a diagnosis of moderate­
severe AD. Similarly, in those diagnosed with severe AD, the number of 
neurofibrillary tangles ranged from 84-120, while a moderate-severe AD 
diagnosis had as little as 11 neurofibrillary tangles. It is, however, 
interesting to note that the greatest number of neuritic plaques overall 
were found in the frontal and temporal lobes as well as in the amygdala, 
areas which are most affected by AD. Also, all patients had the greatest 
number of neurofibrillary tangles in the temporal lobe except one. Patient 
Two had the largest number of neurofibrillary tangles present in the 
amygdala. 
Problems with the cholinergic hypothesis and the variable findings 
in neuritic plaque quantification studies have led to a reexamination of AD 
risk factors so that perhaps a new hypothesis of AD development and 
dementia can be constructed. The hypothesis of AD development and 
dementia examined in this study was that of the relationship between 
atherosclerosis and AD. In particular, atherosclerosis severity and AD 
severity, as well as, atherosclerosis as it relates to AD onset were 
examined. 
Researcher assessment and grouping of patients prior to knowledge 
of autopsy diagnosis was fairly accurate, 57%. That these assessments 
were made only with available records with out medical training is 
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encouraging. If a link between AD and atherosclerosis is established, 
diagnosis of living patients by trained professionals should be very 
accurate and could eventually aid in AD treatment. 
Unfortunately, this study has not established any link between 
atherosclerosis and AD. Because this was a case study analysis, 
statistics could not be used. Furthermore, inferences about AD as it 
relates to atherosclerosis could not be drawn from data gathered on these 
seven patients. 
The range of severity of atherosclerosis corresponding with severe 
AD is too wide to be meaningful. In addition, atherosclerosis was not 
present in two out of five severe AD cases. When looking at duration of 
illness, severe AD with moderate-severe atherosclerosis has the lowest 
duration, one year. However, mild-moderate atherosclerosis with severe 
AD has a much shorter duration than moderate atherosclerosis with severe 
AD, 5 vs. 23 years. Also, the duration of severe AD with mild-moderate 
atherosclerosis is 110 different than that of Patients One and Two who, had 
no associated atherosclerosis. Finally, there are no patterns between age 
of AD onset and presence of atherosclerosis in this data set. Based on 
these results, no meaningful statements about the relationship between 
AD and atherosclerosis can be made. 
A slight increase in differential brain weights between average 
adults and AD patients can be seen as AD illness duration increases. Data 
do not indicate a relationship between duration of illness and cognitive 
test scores. All patients scored in the severe AD dementia range 
regardless of AD duration. Also, there does not appear to be a link 
between cerebral amyloid angiopathy and AD severity at this point in the 
study. 
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It should be noted once again that this data set is extremely small. 
The number of participants in the study continues to grow, and eventually 
statistical analyses will be available. At that point, a pattern between 
AD and atherosclerosis may begin to emerge. For the time being, the small 
data set is a severe limitation to this study. 
Continuous testing of participants every six months and performing 
a brain autopsy on all participants at the time of death are methods not 
common in the current literature on AD and atherosclerosis. This study 
has the potential to advance knowledge of AD when it is finally brought to 
its conclusion. Future researchers may wish to track the time between 
onset and significant downturn of cognitive abilities in AD patients when 
atherosclerosis is present. Finally, a more extensive examination of 
cerebral amyloid angiopathy and its relation to AD severity and 
atherosclerosis severity could be added in the future. 
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